 This is a study to evaluate a new medication dosed once a week in the treatment of bacterial infections in the blood from intravenous catheters CR-BSI. The primary objective is to evaluate the efficacy and safety of dalbavancin in the treatment of adults with CR-BSI relative to a standard of care treatment, vancomycin. 